|
วัลลภา รัตนสวัสดิ์
Department of Internal Medicine, Charoenkrung Pracharak Hospital, Medical Service Department, Bangkok Metropolitan Administration.
ราวิน วงษ์สถาปนาเลิศ
Department of Surgery, Charoenkrung Pracharak Hospital, Medical Service Department, Bangkok Metropolitan Administration
สิริสรรพางค์ ยอดอาวุธ
Department of Pathology, Charoenkrung Pracharak Hospital, Medical Service Department, Bangkok Metropolitan Administration
Abstract
Castleman disease is benign lymph node disease which is rare and most commonly found in thoracic or abdominal cavity. Patient has wide range of symptom such as asymptomatic, flu - like, enlarge lymph nodes, liver and kidney dysfunction and low serum albumin etc. Castleman disease is grouped in unicentric (localized) and multicentric (generalized). It is divided into 3 subtypes as follows 1) Unicentric; most common type and no systemic symptom. Pathological finding always hyaline-vascular subtype
2) Idiopathic multicentric; found in elderly with systemic symptom and may transform into Non-Hodgkin lymphoma 3) Human herpesvirus 8 associated multicentric; immune defect associated with HHV-8 infection which tends to be Non-Hodgkin lymphoma, B cell type. We report unicentric Castleman disease of retroperitoneum area in young male patient with acute abdominal pain was diagnosed acute appendicitis and accidentally found 1retroperitoneum mass by CT scan. Tumor removal was done and histopathological analysis of the tumor showed the hyaline-vascular type of Castleman disease. Patient gained full recovery. We report to realize the rare area presentation of Castleman disease
Keywords: Unicentric Castleman disease: hyaline-vascular, retroperitoneum mass
|
|
|
References
1. Castleman B, Iverson L, Menendez VP. Localized mediastinal lymph node hyperplasia resembling
thymoma. Cancer1956; 9: 822-30.
2. Cronin DM, Warnke RA. Castleman disease an update on classification and the spectrum of
associated lesions. Adv Anat Pathol 2009; 16: 236-46.
3. Nakakura E. Retroperitoneal/abdominal masses [Internet]. 2010[cited 2017 Mar 22]. Available from
www.uscfcmc.com>slides>MSU1001.pdf.
4. Oksenhendler E, Boutboul D, Fajgenbaum D, Mirouse A, Fieschi C, Malphettes M, et al. The full
spectrum of Castleman disease: 273 patients studied over 20 years. British Journal of Hematology
2018; 180(2): 206-16.
5. Talat N, Belgaumkar AP, Schulte KM. Surgery in Castleman’s disease: a systematic review of 404
published cases. Annals of surgery 2012; 255(4): 677-84.
6. Casper C. The etiology and management of Castleman disease at 50 years. Translatiing
pathophysiology to patient care. Br J Haematol 2005; 129(1): 3-17.
7. Shin DY, Jeon YK, Hong YS, Kim TM, Lee SH, Kim DW, et al. Clinical dissection of multicentric
Castleman disease. Leukemia & Lymphoma 2011; 52(8): 1517-22.
8. จักราวดี จุฬามณี, อานุภาพ เลขะกุล. Case discussion I. จุลสารโรคมะเร็งต่อมน้ำเหลือง 2558; (2): 17-
20.
9. Talat N, Belgaumkar AP, Schulte KM. Surgery in Castleman’s disease: a systemic review of 404
published cases. ANN Surg. 2012; 255(4): 677-84.
10. Keller AR, Hochholzer L, Castleman B. Hyaline-vascular and plasma-cell types of giant lymph
node hyperplasia of the mediastinum and other locations. Cancer 1972; 29(3): 670-83.
11. Yoshizaki K, Matsuda T, Nishimoto N, Kuritani T, Taeho L, Aozasak K, et al. Pathogenic
significance of interleukin-6(IL-6/bsf-2) in Castleman’s disease. Blood1989; 47(4): 1360-7.
12. Leger-Ravet MB, Peuchmaur M, Devergne O, Audouin J, Raphael M, Damme JV, et al.
Interleukin-6 gene expression in Castlemas’s disease. Blood 1991; 78(11): 2923-30.
13. Fajgenbaum DC, Uldrick TS, Bagg A, Frank D, Wu D. International, evidence-based consensus
diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease. Blood 2017;
129(12): 1646-57.
14. Talat N, Schulte KM. Castlemam’s disease: systematic analysis of 416 patients from the literature.
Oncologist 2011; 16(9): 1316-24.
15. Chronowski GM, Ha CS, Wilder RB, Cabanillas F, Manning J, Cox JD, et al. Treatment of unicentric
and multicentric Castleman disease and the role of radiotherapy. Cancer 2001; 92: 670. |
|